Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 2/20 | 0.73 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 7/20 | 0.56 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15195013 | 0.90 | SCN9A (0.76) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL6688037 | 0.89 | SCN9A (0.71) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL6688040 | 0.89 | SCN9A (0.71) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL8634796 | 0.89 | SCN9A (0.58) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL965546 | 0.88 | SCN9A (0.57) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL9129379 | 0.86 | SCN9A (0.64) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL1070090 | 0.86 | SCN9A (0.64) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL7396889 | 0.85 | SCN9A (0.63) | SCN9ASCN3AMAOBPARP15PARP14 | |
| SCHEMBL8935406 | 0.85 | SCN9A (0.63) | SCN9ASCN3AMAOBPARP15PARP14 | |
| Ralfinamide SCHEMBL962699 | 0.85 | SCN9A (1.00) | SCN9ASCN3AMAOBPARP15PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2222290-B1 | ALPHA-AMINOAMIDE DERIVATIVES FOR THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARM SPA (IT) | 2021-06-16 | — | — | EP | claimed |
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | claimed |
| US-8741957-B2 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-06-03 | — | — | US | claimed |
| US-8697738-B2 | Alpha-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-04-15 | — | — | US | claimed |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | NEWRON PHARM SPA (US) | 2013-08-22 | — | — | US | claimed |
| US-8445539-B2 | Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2013-05-21 | — | — | US | claimed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | claimed |
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2011-01-20 | — | — | US | claimed |
| EP-1900362-B1 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARM SPA (IT) | 2011-01-12 | — | — | EP | claimed |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | NEWRON PHARMACEUTICALS SPA (IT) | 2010-10-21 | — | — | US | claimed |
| EP-1658062-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2006-05-24 | — | — | EP | claimed |
| US-20060079570-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2006-04-13 | — | — | US | claimed |
| WO-2005102300-A1 | α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-11-03 | — | — | WO | claimed |
| EP-1588704-A1 | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-26 | — | — | EP | claimed |
| EP-1585510-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2005-10-19 | — | — | EP | claimed |
| WO-2005070405-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF LOWER URINARY TRACT DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-08-04 | — | — | WO | claimed |
| EP-1557166-A1 | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | Newron Pharmaceuticals S.p.A. (IT) | 2005-07-27 | — | — | EP | claimed |
| WO-2005018627-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS, SPA (IT) | 2005-03-03 | — | — | WO | claimed |
| WO-2004062655-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTIMIGRAINE AGENTS | NEWRON PHARMACEUTICALS SPA (IT) | 2004-07-29 | — | — | WO | claimed |
| EP-1438956-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | Newron Pharmaceuticals S.p.A. (IT) | 2004-07-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014304-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GABBR1, GABBR2, GABRA5 | SCN9A 1236/4885SCN3A 803/4885MAOB 60/4885 |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | AADAT, PNMT, BCAT2 | SCN9A 946/4885SCN3A 372/4885MAOB 53/4885 |
| US-20060079570-A1 | Alpha-aminoamide derivatives useful as antimigraine agents | AANAT, FAAH, ACHE | SCN9A 27/4885SCN3A 33/4885MAOB 184/4885 |
| US-20100267835-A1 | Methods of treating disorders of trigeminalvascular activation | MVD, TBXA2R, BDKRB2 | SCN9A 1024/4885SCN3A 451/4885MAOB 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.